FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308380055> ?p ?o ?g. }

• W4308380055 abstract "<h3>Background</h3> Adoptive cell therapy with genetically modified T cells has shown promising efficacy in solid tumors but has been limited by immunosuppressive mechanisms that interfere with sustained activity including FAS ligand-induced apoptosis of tumor-infiltrating, FAS receptor-positive lymphocytes.¹ As previously reported, T Cell Receptor (TCR)-engineered T cells expressing a FAS-41BB switch receptor, consisting of FAS extracellular and 41BB intracellular domains, demonstrated improved anti-tumor efficacy.² KRAS is a frequently mutated oncogene in cancers³ and recent clinical evidence suggests that it is immunogenic and targetable via TCR-engineered T cells.⁴ Targeting a mutated oncogenic driver such as KRAS G12V offers many advantages, including tumor dependence driving homogenous expression and decreasing risk of therapeutic escape. We are now reporting an optimized construct that achieves high functional co-expression of the KRAS TCR, CD8ab, and FAS-41BB switch receptor in a single viral vector. <h3>Methods</h3> Human T cells isolated from healthy volunteers were lentivirally transduced with constructs encoding the KRAS TCR, CD8ab chains, and FAS-41BB. Preclinical studies included peptide titrations with the index peptide and ones in which one residue was individually substituted to all possible amino acids (XScan), co-cultures with tumors or B-LCL, and in vivo subcutaneous xenografts. <h3>Results</h3> Co-expression of CD8ab with the KRAS G12V-specific TCR allowed for efficient stimulation of CD4⁺ T cells, and further engineering with the FAS-41BB switch receptor increased sensitivity to low peptide concentrations. In tumor co-culture assays, the inclusion of FAS-41BB allowed for tumor control, even after re-challenge with fresh addition of tumor cells. In a repetitive T cell transfer/tumor exposure assay, continued proliferation and tumor control required both expression of FAS-41BB and inclusion of engineered CD4 and CD8 T cells, suggesting that CD8ab exogenous expression in CD4 T cells allowed for a coordinated T cell response able to resist exhaustion. Intravenous administration of engineered T cells prevented tumor outgrowth <i>in vivo</i>. Using the XScan assay, no off-target liabilities were identified upon co-incubation of A11-KRAS G12V/CD8ab/FAS-41BB switch receptor engineered T cells with all possible peptides in the human proteome matching the recognition motif, demonstrating the specificity of our TCR. No alloreactivity to the most prevalent HLA alleles was detected in B-LCL co-cultures. <h3>Conclusions</h3> Preclinical development of the KRAS G12V-specific TCR with co-expression of CD8ab and the durability FAS-41BB switch receptor supports the clinical development of this first-in-class product for solid tumor patients with high unmet medical needs. <h3>References</h3> Yamamoto TN, Lee P-H, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher J, Cruz AC, Siegel RM, Restifo NP, Klebanoff CA. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. <i>J Clin Invest</i>. 2019;<b>129</b>:1551-1565. Oda SK, Anderson KG, Ravikumar P, Bonson P, Garcia NM, Jenkins CM, Zhuang S, Daman AW, Chiu EY, Bates BM, Greenberg, PD. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. <i>J Exp Med</i>. 2020;<b>217</b>:e20191166. Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. <i>Cancer Res</i>. 2020; <b>80</b>: 2969–2974. Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih Y-P, Leung A, Payne R, Sutcliffe K, Cramer J, Rosenberg SA, Fox BA, Urba WJ, Tran E. Neoantigen T-cell receptor gene therapy in pancreatic cancer. <i>N Engl J Med</i>. 2022;<b>386</b>, 2112–2119. <h3>Ethics Approval</h3> These studies were approved by Affini-T Therapeutics and Fred Hutchinson Cancer Research Center Ethics Boards, approval number EB17-010-303 and PROTO000050898, respectively." @default.
• W4308380055 created "2022-11-11" @default.
• W4308380055 creator A5008827141 @default.
• W4308380055 creator A5019524750 @default.
• W4308380055 creator A5026017810 @default.
• W4308380055 creator A5030463228 @default.
• W4308380055 creator A5032065723 @default.
• W4308380055 creator A5035086451 @default.
• W4308380055 creator A5044650603 @default.
• W4308380055 creator A5062103831 @default.
• W4308380055 creator A5067072586 @default.
• W4308380055 creator A5071689824 @default.
• W4308380055 creator A5083310205 @default.
• W4308380055 creator A5084936176 @default.
• W4308380055 date "2022-11-01" @default.
• W4308380055 modified "2023-10-17" @default.
• W4308380055 title "342 KRAS G12V T cell receptor-engineered T cells expressing the durability FAS-41BB switch receptor exhibit a potent, persistent, coordinated CD4/CD8 anti-tumor response<i>in vitro</i>and<i>in vivo</i>" @default.
• W4308380055 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0342" @default.
• W4308380055 hasPublicationYear "2022" @default.
• W4308380055 type Work @default.
• W4308380055 citedByCount "0" @default.
• W4308380055 crossrefType "proceedings-article" @default.
• W4308380055 hasAuthorship W4308380055A5008827141 @default.
• W4308380055 hasAuthorship W4308380055A5019524750 @default.
• W4308380055 hasAuthorship W4308380055A5026017810 @default.
• W4308380055 hasAuthorship W4308380055A5030463228 @default.
• W4308380055 hasAuthorship W4308380055A5032065723 @default.
• W4308380055 hasAuthorship W4308380055A5035086451 @default.
• W4308380055 hasAuthorship W4308380055A5044650603 @default.
• W4308380055 hasAuthorship W4308380055A5062103831 @default.
• W4308380055 hasAuthorship W4308380055A5067072586 @default.
• W4308380055 hasAuthorship W4308380055A5071689824 @default.
• W4308380055 hasAuthorship W4308380055A5083310205 @default.
• W4308380055 hasAuthorship W4308380055A5084936176 @default.
• W4308380055 hasBestOaLocation W43083800551 @default.
• W4308380055 hasConcept C121608353 @default.
• W4308380055 hasConcept C126322002 @default.
• W4308380055 hasConcept C153911025 @default.
• W4308380055 hasConcept C154317977 @default.
• W4308380055 hasConcept C19317047 @default.
• W4308380055 hasConcept C202751555 @default.
• W4308380055 hasConcept C203014093 @default.
• W4308380055 hasConcept C2776090121 @default.
• W4308380055 hasConcept C2781187634 @default.
• W4308380055 hasConcept C502942594 @default.
• W4308380055 hasConcept C526805850 @default.
• W4308380055 hasConcept C55493867 @default.
• W4308380055 hasConcept C71924100 @default.
• W4308380055 hasConcept C86803240 @default.
• W4308380055 hasConcept C8891405 @default.
• W4308380055 hasConceptScore W4308380055C121608353 @default.
• W4308380055 hasConceptScore W4308380055C126322002 @default.
• W4308380055 hasConceptScore W4308380055C153911025 @default.
• W4308380055 hasConceptScore W4308380055C154317977 @default.
• W4308380055 hasConceptScore W4308380055C19317047 @default.
• W4308380055 hasConceptScore W4308380055C202751555 @default.
• W4308380055 hasConceptScore W4308380055C203014093 @default.
• W4308380055 hasConceptScore W4308380055C2776090121 @default.
• W4308380055 hasConceptScore W4308380055C2781187634 @default.
• W4308380055 hasConceptScore W4308380055C502942594 @default.
• W4308380055 hasConceptScore W4308380055C526805850 @default.
• W4308380055 hasConceptScore W4308380055C55493867 @default.
• W4308380055 hasConceptScore W4308380055C71924100 @default.
• W4308380055 hasConceptScore W4308380055C86803240 @default.
• W4308380055 hasConceptScore W4308380055C8891405 @default.
• W4308380055 hasLocation W43083800551 @default.
• W4308380055 hasOpenAccess W4308380055 @default.
• W4308380055 hasPrimaryLocation W43083800551 @default.
• W4308380055 hasRelatedWork W1971422121 @default.
• W4308380055 hasRelatedWork W2063492259 @default.
• W4308380055 hasRelatedWork W2082500583 @default.
• W4308380055 hasRelatedWork W2095050670 @default.
• W4308380055 hasRelatedWork W2134738680 @default.
• W4308380055 hasRelatedWork W3035321276 @default.
• W4308380055 hasRelatedWork W3167643465 @default.
• W4308380055 hasRelatedWork W4210603573 @default.
• W4308380055 hasRelatedWork W4282947019 @default.
• W4308380055 hasRelatedWork W4288050268 @default.
• W4308380055 isParatext "false" @default.
• W4308380055 isRetracted "false" @default.
• W4308380055 workType "article" @default.